Ascendis Pharma A (ASND) Cash from Operations (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Cash from Operations data on file, last reported at 9039327.16 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 39.96% year-over-year to 9039327.16; the trailing twelve-month figure through Mar 2026 stood at 138536135.97 (up 41.27% YoY), and the FY2025 full-year result was 146404080.93, up 55.82% from the prior year.
• Cash from Operations improved to 9039327.16 in Q1 2026, from 123704068.35 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 2516975.61 in Q3 2025 to a low of 166744814.28 in Q2 2023.
• A 5-year average of 89028542.68 and a median of 99650776.84 in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations sank 103.86% in 2024 and jumped 104.08% in 2025, its largest moves.
• Tracing ASND's Cash from Operations over 5 years: stood at 143506974.16 in 2022, then jumped by 68.16% to 45695167.93 in 2023, then slumped by 103.86% to 93155872.6 in 2024, then slumped by 32.79% to 123704068.35 in 2025, then jumped by 92.69% to 9039327.16 in 2026.
• Business Quant data shows ASND's Cash from Operations at 9039327.16 in Q1 2026, 123704068.35 in Q4 2025, and 2516975.61 in Q3 2025.